GSK plc (LSE/NYSE: GSK) today announced positive headline results of a phase II trial (NCT06431607) for its mRNA seasonal influenza vaccine programme. The trial studied a range of mRNA formulations in older and younger adults to evaluate vaccine candidates that could improve immune responses against influenza A and B strains, compared to the current standard of care..

葛兰素史克股份有限公司（LSE/NYSE:GSK）今天宣布其mRNA季节性流感疫苗计划的II期试验（NCT06431607）的正面标题结果。该试验研究了老年人和年轻人的一系列mRNA制剂，以评估与目前的护理标准相比，可以改善针对甲型和乙型流感病毒株的免疫应答的候选疫苗。。

In both younger and older adults, pre-defined success criteria were met. Interim data suggest the vaccine candidates have an acceptable safety and reactogenicity profile for all mRNA formulations tested.

在年轻人和老年人中，都符合预定义的成功标准。中期数据表明，候选疫苗对所有测试的mRNA制剂具有可接受的安全性和反应原性。

These results build on the previous phase II trial and confirm the mRNA platform elicits strong overall antibody titres with an acceptable safety profile. With these results, the GSK mRNA seasonal influenza vaccine programme will progress into late-stage clinical development.

这些结果建立在之前的II期试验的基础上，并证实mRNA平台引发了强大的整体抗体滴度，具有可接受的安全性。有了这些结果，GSK mRNA季节性流感疫苗计划将进入晚期临床开发阶段。

GSK’s Chief Scientific Officer, Tony Wood said: “This marks a significant advancement in our mRNA programme and these data support moving into late-stage development. Ultimately, our goal is to develop a new best-in-class vaccine to bring greater protection to people through the influenza season.”

葛兰素史克首席科学官托尼·伍德说：“这标志着我们的mRNA计划取得了重大进展，这些数据支持进入后期开发阶段。最终，我们的目标是开发一种新型一流的疫苗，在流感季节为人们带来更大的保护。”

GSK recently signed a new licensing agreement with CureVac to assume full control of developing and manufacturing influenza and COVID-19 candidate vaccines. GSK continues to develop and optimise its mRNA capabilities through investments and partnerships, including in AI/ML-based sequence optimisation, nanoparticle design and manufacturing..

葛兰素史克（GSK）最近与CureVac签署了一项新的许可协议，全面控制流感和新型冠状病毒（COVID-19）候选疫苗的开发和生产。GSK继续通过投资和合作伙伴关系开发和优化其mRNA能力，包括基于AI/ML的序列优化，纳米粒子设计和制造。。

About study NCT06431607

关于研究NCT06431607

The phase II study assesses the reactogenicity, safety, and immunogenicity of different dose levels of a modified, multivalent vaccine candidate, encoding antigens matched to all three WHO-recommended influenza strains. The study includes 250 healthy younger adults aged 18 to 64 and 250 healthy older adults aged 65 to 85.

II期研究评估了不同剂量水平的修饰多价候选疫苗的反应原性，安全性和免疫原性，该候选疫苗编码与世卫组织推荐的所有三种流感病毒株相匹配的抗原。这项研究包括250名18至64岁的健康年轻人和250名65至85岁的健康老年人。

In each age group, different dose levels were tested in comparison to an age-appropriate, licensed comparator vaccine..

在每个年龄组中，与适合年龄的许可比较疫苗相比，测试了不同的剂量水平。。

About GSK

GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

葛兰素史克是一家全球性生物制药公司，旨在将科学、技术和人才团结起来，共同战胜疾病。更多信息请访问gsk.com。